Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Transcriptional repression by the HDAC4–RelB–p52 complex regulates multiple myeloma survival and growth
Subrahmanya Vallabhapurapu, Sunil K. Noothi, Derek A. Pullum, Charles H. Lawrie, Rachel R. Pallapati, Veena Potluri, Christian Kuntzen, SA Khan, David R. Plas, Robert Z. Orlowski, Marta Chesi, W. Michael Kuehl, P. Leif Bergsagel, Michael Karin, Sivakumar Vallabhapurapu (2015). Transcriptional repression by the HDAC4–RelB–p52 complex regulates multiple myeloma survival and growth. , 6(1), DOI: https://doi.org/10.1038/ncomms9428.
Article57 days agoIsatuximab for the treatment of multiple myeloma: current clinical advances and future directions
Paul G. Richardson, Elisabeth K. O’Donnell, Peter O’Gorman, Lisa Leypoldt, Jacob P. Laubach, Francesca Gay, Xavier Leleu, Thierry Façon, Philippe Moreau, Meletios A Dimopoulos, Hartmut Goldschmidt, K. Elias, Michèle Cavo, Katja Weisel, Jesús G. Berdeja, Robert Z. Orlowski, Meral Beksaç, Aurore Perrot, Joseph Mıkhael, T. John Martin (2025). Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions. , 34(7-8), DOI: https://doi.org/10.1080/13543784.2025.2532446.
Article41 days agoIsatuximab plus bortezomib, lenalidomide, and dexamethasone for transplantineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial
Salomon Manier, Meletios A Dimopoulos, Xavier P. Leleu, Philippe Moreau, Michèle Cavo, Hartmut Goldschmidt, Robert Z. Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T. Shafer, Meral Beksac, Thierry Façon (2025). Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplantineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial. , 110(9), DOI: https://doi.org/10.3324/haematol.2024.287200.
Article41 days agoP-426 Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ
Salomon Manier, Meletios A Dimopoulos, Xavier Leleu, Philippe Moreau, Michèle Cavo, Hartmut Goldschmidt, Robert Z. Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T. Shafer, Meral Beksaç, Thierry Façon (2024). P-426 Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ. , 24, DOI: https://doi.org/10.1016/s2152-2650(24)02347-4.
Article41 days agoPhase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).
Thierry Façon, Meletios A Dimopoulos, Xavier Leleu, Meral Beksaç, Luděk Pour, Roman Hájek, Zhuogang Liu, Jiří Minařík, Philippe Moreau, Joanna Romejko‐Jarosińska, Ivan Špıčka, Vladimir Vorobyev, Michèle Cavo, Hartmut Goldschmidt, Thomas G. Martin, Salomon Manier, Marie-France Brégeault, Sandrine Macé, Christelle Berthou, Robert Z. Orlowski (2024). Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).. , 42(16_suppl), DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.7500.
Article41 days ago